KalGene Pharmaceuticals Inc., NRC, CIMTEC and McGill to Present Ground-Breaking Preclinical Data During Alzheimer’s Disease Program at AAIC 2017

KalGene Pharmaceuticals Inc., NRC, CIMTEC and McGill to Present Ground-Breaking Preclinical Data During Alzheimer’s Disease Program at AAIC 2017

KalGene Pharmaceuticals Inc., in collaboration with the National Research Council of Canada (NRC), CIMTEC and the McGill Centre for Studies in Aging, have demonstrated that KalGene’s Alzheimer’s therapeutics candidate, licensed from the NRC (KAL-ABP-BBB), crosses the blood-brain barrier, and reduces amyloid-beta burden in a transgenic rat model after a four (4) week treatment. The results will be presented by McGill’s Dr. Pedro Rosa-Neto and the NRC’s Dr. Balu Chakravarthy at the Alzheimer’s Association International Conference (AAIC) in London in July 2017.

Click here to read more.

Read More

NRC and KalGene Develop New Alzheimer's Treatment

Canadian biotech KalGene Pharmaceuticals has successfully secured $1.5 million in financing from Brain Canada, CQDM, and the Ontario Brain Institute (OBI) Focus on Brain program to develop a new treatment for Alzheimer's. This funding from CQDM will allow KalGene to test the conjugated therapeutic in preclinical models and if successful, in patients. 

Read more.